Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Income from Continuing Operations of $25.43 million for Q2 2026, up 42.6% from $17.83 million a year earlier and up 12.6% from the prior quarter.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2017 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Income from Continuing Operations at Kiniksa Pharmaceuticals International was $80.66 million; for FY2025, it was $59.01 million.
- In prior years, Kiniksa Pharmaceuticals International's Income from Continuing Operations was -$43.19 million in FY2024, $14.08 million in FY2023 (-92.3%), $183.36 million in FY2022 and -$157.92 million in FY2021.
- The Q2 2026 figure stands as the highest quarterly Income from Continuing Operations since Q3 2022.
- According to Business Quant data, Income from Continuing Operations for the three prior quarters was $22.59 million (Q1 2026), $14.2 million (Q4 2025) and $18.44 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Kiniksa Pharmaceuticals International | 11.64 Bn | 10.38 Bn | 220.03 Mn | 25.43 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.43 Mn |
| Mar 31, 2026 | 22.59 Mn |
| Dec 31, 2025 | 14.20 Mn |
| Sep 30, 2025 | 18.44 Mn |
| Jun 30, 2025 | 17.83 Mn |
| Mar 31, 2025 | 8.54 Mn |
| Dec 31, 2024 | -8.89 Mn |
| Sep 30, 2024 | -12.69 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -17.70 Mn |
| Dec 31, 2023 | 25.24 Mn |
| Sep 30, 2023 | -13.86 Mn |
| Jun 30, 2023 | 14.97 Mn |
| Mar 31, 2023 | -12.27 Mn |
| Dec 31, 2022 | 4.46 Mn |
| Sep 30, 2022 | 224.09 Mn |
| Jun 30, 2022 | -19.98 Mn |
| Mar 31, 2022 | -25.21 Mn |
| Dec 31, 2021 | -36.33 Mn |
| Sep 30, 2021 | -30.54 Mn |
API Access
Kiniksa Pharmaceuticals International Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=KNSA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "KNSA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=KNSA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();